Advanced search

Authors whose works are in public domain in at least one jurisdiction

List of works by Tara C Gangadhar

140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)

article

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

scientific article (publication date: November 2016)

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma

scientific article published in November 2017

A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors

scientific article published on 19 October 2017

Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome

article

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

scientific article (publication date: 20 September 2014)

Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma

scientific article published on 16 November 2017

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

scientific article published on April 2016

BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth

scientific article

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

article

Broad Applicability of Nivolumab in Melanoma Regardless of BRAF Mutation Status

scientific article published in July 2015

Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

scientific article published on 04 February 2016

Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types

scientific article

Complete Response of Advanced Melanoma Treated With Talimogene Laherparepvec and Subsequent Sweet's-like Infiltrate

scientific article published on 01 July 2017

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

scientific article published on 01 December 2018

Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma

scientific article published on 10 May 2016

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

scientific article published on 28 December 2017

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.

scientific article published on November 2017

Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL)

article

Enhancing the evaluation of PI3K inhibitors through 3D melanoma models

scientific article

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

scientific article published on 07 March 2016

FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial

scientific article published on 10 January 2018

Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma

scientific article published on 8 August 2017

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

scientific article published on 26 September 2017

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research ⬇️

scientific article published on January 22, 2011

Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines

scientific article published in November 2017

Improving the Safety of Oral Chemotherapy at an Academic Medical Center

scientific article published on 05 January 2016

LBA34PEMBROLIZUMAB (PEMBRO; MK-3475) FOR ADVANCED MELANOMA (MEL): RANDOMIZED COMPARISON OF TWO DOSING SCHEDULES

article

Lichen planopilaris associated with pembrolizumab in a patient with metastatic melanoma.

scientific article published on 16 January 2018

Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma

scholarly article by David L Bajor et al published 2018 in OncoImmunology

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

scientific article

Mitigating the toxic effects of anticancer immunotherapy

scientific article published on 21 January 2014

Molecular markers to individualize adjuvant therapy for colon cancer

scientific article published on 04 May 2010

Novel risk scores for survival and intracranial failure in patients treated with radiosurgery alone to melanoma brain metastases

scientific article

P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma

article

Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC).

scientific article published on 6 November 2014

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

scientific article

Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma ⬇️

scientific article published on November 15, 2012

Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers

scientific article published on 4 November 2015

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma

scientific article published on 31 October 2016

Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database ⬇️

scientific article published on February 28, 2011

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

scientific article

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

scientific article

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

scientific article (publication date: 11 July 2013)

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

scientific article published on 10 April 2017

Takotsubo cardiomyopathy in a patient with esophageal cancer: a case report

scientific article published on 08 December 2008

Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors

scientific article published on 4 April 2016

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma

scientific article published on 4 September 2015

The efficacy of anti-PD-1 agents in acral and mucosal melanoma

scientific article published on 17 August 2016

The role of chemokine receptor CXCR4 in lung cancer

scientific article published on 18 March 2010

The role of the c-Met pathway in lung cancer and the potential for targeted therapy ⬇️

scientific article published on July 1, 2011

Treatment options for metastatic melanoma in solid organ transplant recipients

scientific article published on 24 November 2015

Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade

scientific article published on December 2016

Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies ⬇️

scientific article published on March 29, 2011

Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption

scientific article

Paulina is supported by:

About Paulina

Help